Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuangshi Tonglin capsules for lower urinary tract irritation-related diseases
ChiCTR2300071809Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shuangshi Tonglin capsules in chronic prostatitis (CP), acute cystitis and urethritis (4 cohorts), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Lower urinary tract irritation symptom score and TCM symptom effectiveness at different time points. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Shuangshi Tonglin capsules
03
Conditions
chronic prostatitis (CP)acute cystitisurethritis
Beyond the preview
Go deeper on ChiCTR2300071809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071809.